Emerging Therapies for Hypercortisolism

This episode, titled ‘Emerging Therapies for Hypercortisolism,’ features panelists discussing the evolving treatment landscape for hypercortisolism and the growing body of research aimed at improving outcomes for patients with resistant hypertension, diabetes, and other cardiometabolic complications. Expert cardiology faculty explore how recent clinical studies have expanded awareness of hypercortisolism and highlight the importance of developing targeted therapies that address the underlying drivers of disease.

The panel examines current and investigational treatment approaches, including glucocorticoid receptor modulation and other emerging therapeutic strategies designed to more selectively target cortisol-related pathways. They discuss lessons learned from existing therapies and consider how newer agents may help overcome some of the limitations and adverse effects associated with earlier treatment options. Throughout the conversation, the expert faculty emphasize the need for continued clinical research to better define the role of these therapies in patients with varying degrees of cortisol excess.

The panelists also explore broader questions regarding disease characterization and treatment thresholds, including how future studies may help refine the definition of clinically meaningful cortisol elevation and identify patients most likely to benefit from intervention. They discuss the importance of randomized clinical trials and the role of surrogate markers such as blood pressure and glycemic control in demonstrating therapeutic benefit.

As the field continues to evolve, the panel highlights the potential for more selective therapies to expand treatment options and improve integration into cardiovascular practice. The discussion provides valuable insight into the future direction of hypercortisolism research and the opportunities that emerging therapies may create for patients with complex cardiometabolic disease.

The next episode in this series, ‘The Future of Hypercortisolism Care in Cardiology,’ features the panelists discussing how advances in hypercortisolism screening, treatment, and multidisciplinary care may transform the management of resistant hypertension and cardiometabolic disease. They explore the evolving role of cardiologists in identifying and coordinating care for patients with cortisol-related cardiovascular risk.